Companies /Healthcare
Incyte Corp
NASDAQ: INCY Biotechnology
$117.80
▼ $1.29 (−1.08%) today
Markets closed · 11:13pm ET

Incyte (INCY) Q3 2026 Earnings

Reported Oct 29, 2026, 7:03am ET · SEC source
$-3.60
Beat +6.14%
EPS · est. $-3.84 Adjusted

Includes a one-time $1.23 billion IPR&D expense related to the acquisition of Vega Therapeutics (included in both GAAP and non-GAAP R&D); GAAP diluted EPS was $(3.86).

$1.6B
Beat +5.55%
Revenue · est. $1.5B
3 quarters
Consecutive EPS beats

How Did INCY Stock React to Q3 2026 Earnings?

% change · around the report
−8%−4%0+4%Oct 29Oct 30report 7:03am ETearnings−2.0%+2.8%
−8%−4%0+4%Oct 29Oct 30earnings−2.0%+2.8%
INCY +2.8%S&P 500 −2.0%
−8%−4%0+4%Oct 29Oct 30report 7:03am ETearnings−4.1%+2.8%
−8%−4%0+4%Oct 29Oct 30earnings−4.1%+2.8%
INCY +2.8%NASDAQ −4.1%
−3%0+3%Oct 28Nov 6report 7:03am ETearnings−4.6%+2.1%
−3%0+3%Oct 28Nov 6earnings−4.6%+2.1%
INCY +2.1%S&P 500 −4.6%
−10%−5%0+5%Oct 28Nov 6report 7:03am ETearnings−8.4%+2.1%
−10%−5%0+5%Oct 28Nov 6earnings−8.4%+2.1%
INCY +2.1%NASDAQ −8.4%
−0.06%
Day of report
+3.07%
Next session
+1.04%
One week

Did INCY Beat Earnings? Q3 2026 Results

Yes. Incyte reported Q3 2026 earnings of $-3.60 a share on Oct 29, 2026, beating the $-3.84 consensus estimate by 6.1%. Revenue was $1.6B against a $1.5B estimate.

Incyte Corporation posted a stronger-than-expected third quarter of fiscal 2026, beating Wall Street on both the top and bottom lines despite absorbing a substantial acquisition charge that drove a wide net loss. Revenue climbed 14.0% year over year to $1.56 billion, ahead of the $1.48 billion consensus by 5.55%, while adjusted non-GAAP EPS came in at a loss of $3.60, beating the $3.84 consensus estimate by 6.14%. The headline loss reflected a $1.23 billion in-process research and development charge tied to Incyte's July acquisition of Vega Therapeutics, which brought the Phase 3 latarcibart program for von Willebrand disease into the pipeline. Underneath that charge, commercial momentum was broad-based, with Opzelura growing 36% and the Hematology and Oncology portfolio advancing 38%, led by triple-digit growth in Zynyz. Incyte raised its full-year total net sales guidance to $5.21 billion to $5.30 billion and lifted its Opzelura outlook to $1.10 billion to $1.12 billion, with investors also watching promising ESMO data for INCB161734 in pancreatic cancer as a key longer-term growth driver.

Key Takeaways
  • Jakafi growth driven by a 12% increase in paid demand and growth across all indications
  • Opzelura growth driven by increased patient demand in atopic dermatitis and vitiligo and improved net pricing following the line extension settlement
  • Hematology and Oncology growth driven by increased demand for Niktimvo, Zynyz and Monjuvi/Minjuvi
  • $1.23 billion one-time IPR&D expense from the Vega acquisition drove the operating and net loss
  • SG&A increase primarily due to pre-launch activities

“Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements. Net sales growth was strong in both the U.S. and internationally, creating a durable core business beyond Jakafi.”

Incyte CEO, on the earnings call

What Is Incyte's Outlook?

Incyte raised its full-year 2026 guidance on continued strong performance across the portfolio: - Total net sales: $5,210–$5,300 million (previously $5,130–$5,260 million). - Opzelura net sales: $1,100–$1,120 million (previously $1,050–$1,100 million), including a one-time $246 million CMS-related benefit. - Hematology and Oncology net sales: $890–$910 million (previously $860–$890 million). It reaffirmed the remaining guidance: - Jakafi net sales: $3,220–$3,270 million. - Total GAAP R&D and SG&A expenses: $4,915–$4,995 million, including the $1.23 billion Vega IPR&D charge. - Total non-GAAP R&D and SG&A expenses: $4,625–$4,695 million. Near-term catalysts include: - Q4 2026 Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in HS. - An EC decision on povorcitinib in HS. - Potential Q1 2027 U.S. approvals and launches for povorcitinib in HS and Monjuvi in newly diagnosed DLBCL. Management expects multiple paths to growth beyond 2029.

INCY YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$500.0M$1.0B$1.5B$1.4B$1.6BRevenue
$0$500.0M$1.0B$1.5BRevenue
INCY income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $1.6B $1.4B +14.0%

INCY Revenue by Segment

Jakafi$826.5M+4.0%
Opzelura$254.9M+36.0%
Jakavi Royalties$132.5M+5.0%
Niktimvo$67.4M+47.0%
Zynyz$58.3M+157.0%
Monjuvi$54.6M+30.0%
Milestone and Contract Revenues$49.8M+11.0%
Olumiant Royalties$39.1M+5.0%

When Does Incyte Report Next?

Expected report date
After the close
Release timing

Figures from SEC filings and company reports. Not investment advice.